BioCryst Pharmaceuticals, Inc. is a biotechnology company. The company is headquartered in Durham, North Carolina and currently employs 580 full-time employees. The firm leverages its expertise in designing to develop first-in-class oral small-molecule and protein therapeutics to target difficult-to-treat diseases. Its marketed products include oral, once-daily ORLADEYO for the prevention of hereditary angioedema (HAE) attacks and RAPIVAB (peramivir injection) for the treatment of acute uncomplicated influenza in the United States. Its other products and product candidates include BCX10013, RAPIACTA (peramivir injection), PERAMIFLU (peramivir injection), and early-stage discovery programs. BCX10013, is a potent and specific Factor D inhibitor. RAPIACTA focuses on uncomplicated seasonal influenza. The RAPIVAB (peramivir injection) is approved in the United States for the treatment of acute uncomplicated influenza for patients six months and older.
Follow-Up Questions
Qui est le CEO de BioCryst Pharmaceuticals Inc ?
Mr. Jon Stonehouse est le President de BioCryst Pharmaceuticals Inc, il a rejoint l'entreprise depuis 2007.
Quelle est la performance du prix de l'action BCRX ?
Le prix actuel de BCRX est de $6.56, il a decreased de 0.97% lors de la dernière journée de trading.
Quels sont les thèmes d'affaires principaux ou les industries de BioCryst Pharmaceuticals Inc ?
BioCryst Pharmaceuticals Inc appartient à l'industrie Biotechnology et le secteur est Health Care
Quelle est la capitalisation boursière de BioCryst Pharmaceuticals Inc ?
La capitalisation boursière actuelle de BioCryst Pharmaceuticals Inc est de $1.3B
Est-ce que BioCryst Pharmaceuticals Inc est un achat, une vente ou un maintien ?
Selon les analystes de Wall Street, 14 analystes ont établi des notations d'analystes pour BioCryst Pharmaceuticals Inc, y compris 5 achat fort, 11 achat, 2 maintien, 0 vente et 5 vente forte
